Cargando…
IL-6 Inhibition in Critically Ill COVID-19 Patients Is Associated With Increased Secondary Infections
Background: Anti-inflammatory therapies such as IL-6 inhibition have been proposed for COVID-19 in a vacuum of evidence-based treatment. However, abrogating the inflammatory response in infectious diseases may impair a desired host response and pre-dispose to secondary infections. Methods: We retros...
Autores principales: | Kimmig, Lucas M., Wu, David, Gold, Matthew, Pettit, Natasha N., Pitrak, David, Mueller, Jeffrey, Husain, Aliya N., Mutlu, Ece A., Mutlu, Gökhan M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7655919/ https://www.ncbi.nlm.nih.gov/pubmed/33195334 http://dx.doi.org/10.3389/fmed.2020.583897 |
Ejemplares similares
-
Secondary infections in critically ill patients with COVID-19 receiving
steroid therapy
por: Pearce, Alex K, et al.
Publicado: (2023) -
SARS-CoV-2 Infection Is Associated with Reduced Krüppel-like Factor 2 in Human Lung Autopsy
por: Wu, David, et al.
Publicado: (2021) -
Incidence of Secondary Hemophagocytic Lymphohistiocytosis in Critically-Ill COVID-19 Patients
por: Allen, Jamie, et al.
Publicado: (2021) -
Head CT is of limited diagnostic value in critically ill patients who remain unresponsive after discontinuation of sedation
por: Balachandran, Jay S, et al.
Publicado: (2009) -
Endogenous itaconate is not required for particulate matter-induced NRF2 expression or inflammatory response
por: Sun, Kaitlyn A, et al.
Publicado: (2020)